Inhibition of CDK7, CDK9 or CDK12 affects phosphorylation of human SPT5. https://www.biorxiv.org/content/10.64898/2026.10.26.761550v1
October 28, 2026 at 8:17 PM
Inhibition of CDK7, CDK9 or CDK12 affects phosphorylation of human SPT5. https://www.biorxiv.org/content/10.64898/2026.10.26.761550v1
Inhibition of CDK7, CDK9 or CDK12 affects phosphorylation of human SPT5. https://www.biorxiv.org/content/10.64898/2026.10.26.761550v1
October 28, 2026 at 8:17 PM
Inhibition of CDK7, CDK9 or CDK12 affects phosphorylation of human SPT5. https://www.biorxiv.org/content/10.64898/2026.10.26.761550v1
Effective treatment of #HNSCC demands novel therapeutic strategies.
This article evaluates #CDK7 inhibition, describing potent antitumor activity, cell cycle disruption, and preclinical efficacy. @universidadoviedo.bsky.social
#STTT #OpenAccess: doi.org/10.1038/s413...
This article evaluates #CDK7 inhibition, describing potent antitumor activity, cell cycle disruption, and preclinical efficacy. @universidadoviedo.bsky.social
#STTT #OpenAccess: doi.org/10.1038/s413...
October 25, 2026 at 3:00 AM
Effective treatment of #HNSCC demands novel therapeutic strategies.
This article evaluates #CDK7 inhibition, describing potent antitumor activity, cell cycle disruption, and preclinical efficacy. @universidadoviedo.bsky.social
#STTT #OpenAccess: doi.org/10.1038/s413...
This article evaluates #CDK7 inhibition, describing potent antitumor activity, cell cycle disruption, and preclinical efficacy. @universidadoviedo.bsky.social
#STTT #OpenAccess: doi.org/10.1038/s413...
Meme kanserinde dirençli vakalarda CDK7 inhibitörü kombinasyonu 59 hastada umut verdi
Meme kanseri tedavisinde zamanla gelişen ilaç direnci, hastaların tedaviye yanıt verme süresini kısıtlayan en büyük engellerden biri olarak öne çıkarken; Nature Communications dergisinde yayımlanan son araştırma…
Meme kanseri tedavisinde zamanla gelişen ilaç direnci, hastaların tedaviye yanıt verme süresini kısıtlayan en büyük engellerden biri olarak öne çıkarken; Nature Communications dergisinde yayımlanan son araştırma…
Meme kanserinde dirençli vakalarda CDK7 inhibitörü kombinasyonu 59 hastada umut verdi
Meme kanseri tedavisinde zamanla gelişen ilaç direnci, hastaların tedaviye yanıt verme süresini kısıtlayan en büyük engellerden biri olarak öne çıkarken; Nature Communications dergisinde yayımlanan son araştırma bu direnci kırmaya yönelik…
haberdal.com
October 22, 2026 at 7:35 AM
Meme kanserinde dirençli vakalarda CDK7 inhibitörü kombinasyonu 59 hastada umut verdi
Meme kanseri tedavisinde zamanla gelişen ilaç direnci, hastaların tedaviye yanıt verme süresini kısıtlayan en büyük engellerden biri olarak öne çıkarken; Nature Communications dergisinde yayımlanan son araştırma…
Meme kanseri tedavisinde zamanla gelişen ilaç direnci, hastaların tedaviye yanıt verme süresini kısıtlayan en büyük engellerden biri olarak öne çıkarken; Nature Communications dergisinde yayımlanan son araştırma…
The authors included RRIDs in their in Journal of Translational Medicine paper! Thanks for making your methods matter! #OpenResearch #methodsmatter #accelerateopenscience
Targeting super-enhancer-driven SKIL transcription by CDK7 inhibitor THZ1 to suppress gastric cancer progression
Read the full paper: Targeting super-enhancer-driven SKIL transcription by CDK7 inhibitor THZ1 to suppress gastric cancer progression
doi.org
October 9, 2026 at 7:04 AM
The authors included RRIDs in their in Journal of Translational Medicine paper! Thanks for making your methods matter! #OpenResearch #methodsmatter #accelerateopenscience
Sensitizing tumor response to topoisomerase I antibody-drug conjugate by selective CDK7 inhibition
Science Advances
www.science.org/doi/10.1126/...
Science Advances
www.science.org/doi/10.1126/...
Sensitizing tumor response to topoisomerase I antibody-drug conjugate by selective CDK7 inhibition
This study investigates the transcriptional impact of Q901, a highly selective cyclin-dependent kinase 7 (CDK7) inhibitor in clinical development. Q901 primarily disrupted MYC and E2F-dependent transc...
www.science.org
October 1, 2026 at 7:15 AM
Sensitizing tumor response to topoisomerase I antibody-drug conjugate by selective CDK7 inhibition
Science Advances
www.science.org/doi/10.1126/...
Science Advances
www.science.org/doi/10.1126/...
Qurient Announces Publication in Science Advances Demonstrating Synergistic Effect of Selective CDK7 Inhibitor Q901 with TOP1 Inhibitor-Based ADCs
https://www.byteseu.com/2413022/
Peer-reviewed study provides the mechanistic foundation for combining CDK7 and TOP1 inhibitors, validating …
https://www.byteseu.com/2413022/
Peer-reviewed study provides the mechanistic foundation for combining CDK7 and TOP1 inhibitors, validating …
Qurient Announces Publication in Science Advances Demonstrating Synergistic Effect of Selective CDK7 Inhibitor Q901 with TOP1 Inhibitor-Based ADCs - Bytes Europe
SEONGNAM, South Korea--(BUSINESS WIRE)--#ADC--Qurient Co., Ltd. (KRX: 115180), a clinical-stage biotechnology company developing innovative cancer
www.byteseu.com
October 1, 2026 at 4:00 AM
Qurient Announces Publication in Science Advances Demonstrating Synergistic Effect of Selective CDK7 Inhibitor Q901 with TOP1 Inhibitor-Based ADCs
https://www.byteseu.com/2413022/
Peer-reviewed study provides the mechanistic foundation for combining CDK7 and TOP1 inhibitors, validating …
https://www.byteseu.com/2413022/
Peer-reviewed study provides the mechanistic foundation for combining CDK7 and TOP1 inhibitors, validating …
An inducible multiciliated cell line resolves proteome dynamics and identifies CDK7 as a conserved regulator. From Camille Boutin @camboutin.bsky.social, Laurent Kodjabachian and colleagues: rupress.org/jcb/article/...
📕 Part of #Centrosomes and #Cilia 2026: rupress.org/jcb/collecti...
📕 Part of #Centrosomes and #Cilia 2026: rupress.org/jcb/collecti...
August 24, 2026 at 3:16 PM
An inducible multiciliated cell line resolves proteome dynamics and identifies CDK7 as a conserved regulator. From Camille Boutin @camboutin.bsky.social, Laurent Kodjabachian and colleagues: rupress.org/jcb/article/...
📕 Part of #Centrosomes and #Cilia 2026: rupress.org/jcb/collecti...
📕 Part of #Centrosomes and #Cilia 2026: rupress.org/jcb/collecti...
The study here: ashpublications.org/bloodneoplas...
Predictors of response to venetoclax and therapeutic potential of CDK7 inhibition in multiple myeloma
Key PointsRNA-seq analysis reveals a 6-gene signature that stratifies patients with MM by their predicted response to venetoclax.This study proposes a nove
ashpublications.org
November 30, 2024 at 7:17 PM
The study here: ashpublications.org/bloodneoplas...
1️⃣ Venetoclax works best for patients with t(11;14), but those with 1q gain are often resistant.
2️⃣ A six-gene signature helps predict response, providing a potential tool for precision medicine.
3️⃣ Excitingly, CDK7 inhibitors may help overcome resistance in patients with 1q gain.
2️⃣ A six-gene signature helps predict response, providing a potential tool for precision medicine.
3️⃣ Excitingly, CDK7 inhibitors may help overcome resistance in patients with 1q gain.
November 30, 2024 at 7:17 PM
1️⃣ Venetoclax works best for patients with t(11;14), but those with 1q gain are often resistant.
2️⃣ A six-gene signature helps predict response, providing a potential tool for precision medicine.
3️⃣ Excitingly, CDK7 inhibitors may help overcome resistance in patients with 1q gain.
2️⃣ A six-gene signature helps predict response, providing a potential tool for precision medicine.
3️⃣ Excitingly, CDK7 inhibitors may help overcome resistance in patients with 1q gain.
Excited to share our latest work in #MultipleMyeloma! 🧬 We uncovered a six-gene signature predicting response to venetoclax, but also revealed that 1q gain can drive resistance—and how CDK7 inhibitors might reverse it. #MyelomaResearch
Mount Sinai Researchers Identify Six-Gene Pattern to Predict Drug Success in Multiple Myeloma Patients
www.mountsinai.org
November 30, 2024 at 7:17 PM
Excited to share our latest work in #MultipleMyeloma! 🧬 We uncovered a six-gene signature predicting response to venetoclax, but also revealed that 1q gain can drive resistance—and how CDK7 inhibitors might reverse it. #MyelomaResearch
Our paper showing that acquired resistance to CDK inhibitors can result from simple mutations in the CDK gene is now out - thanks to Chun-Fui Lai, @vcushing.bsky.social @bjgreber.bsky.social with support from @prostatecanceruk.bsky.social @imperialsandc.bsky.social www.embopress.org/doi/full/10....
Resistance to CDK7 inhibitors directed by acquired mutation of a conserved residue in cancer cells | The EMBO Journal
imageimageCDKs control cell cycle progression and transcription, pathways commonly dysregulated
in cancer. This study identifies a resistance mechanism of prostate cancer cells towards
the CDK7 inhibi...
www.embopress.org
October 16, 2025 at 8:26 AM
Our paper showing that acquired resistance to CDK inhibitors can result from simple mutations in the CDK gene is now out - thanks to Chun-Fui Lai, @vcushing.bsky.social @bjgreber.bsky.social with support from @prostatecanceruk.bsky.social @imperialsandc.bsky.social www.embopress.org/doi/full/10....
We show a single amino acid change in CDK7 causes acquired resistance to CDK7i in cancer cells. There are implications for patient selection,resistance monitoring and switching treatments. thanks to @vcushing.bsky.social @bjgreber.bsky.social @prostatecanceruk.bsky.social
doi.org/10.1038/s443...
doi.org/10.1038/s443...
September 8, 2025 at 7:18 PM
We show a single amino acid change in CDK7 causes acquired resistance to CDK7i in cancer cells. There are implications for patient selection,resistance monitoring and switching treatments. thanks to @vcushing.bsky.social @bjgreber.bsky.social @prostatecanceruk.bsky.social
doi.org/10.1038/s443...
doi.org/10.1038/s443...
Bonner Forscher äußern sich zur Wirkweise des Eiweißes Cdk7 und dessen möglichen Rolle in der Krebstherapie
Etwa jeder vierte Todesfall in Deutschland ist im letzten Jahr auf Krebskrankheiten zurückzuführen. Bei der Suche nach neuen Therap...
weiterlesen
Etwa jeder vierte Todesfall in Deutschland ist im letzten Jahr auf Krebskrankheiten zurückzuführen. Bei der Suche nach neuen Therap...
weiterlesen
September 19, 2024 at 6:59 AM
Bonner Forscher äußern sich zur Wirkweise des Eiweißes Cdk7 und dessen möglichen Rolle in der Krebstherapie
Etwa jeder vierte Todesfall in Deutschland ist im letzten Jahr auf Krebskrankheiten zurückzuführen. Bei der Suche nach neuen Therap...
weiterlesen
Etwa jeder vierte Todesfall in Deutschland ist im letzten Jahr auf Krebskrankheiten zurückzuführen. Bei der Suche nach neuen Therap...
weiterlesen
How To's Community Outreach || 12.17.25
How do you build a community garden in a place where resources are limited — and safety is a real concern?
www.youtube.com/watch?v=cDK7...
How do you build a community garden in a place where resources are limited — and safety is a real concern?
www.youtube.com/watch?v=cDK7...
How To's Community Outreach || 12.17.25
How do you build a community garden in a place where resources are limited — and safety is a real concern?
In this episode of Collectively Rewilding, we support Candace (a member of our community)…
www.youtube.com
January 9, 2026 at 2:01 AM
How To's Community Outreach || 12.17.25
How do you build a community garden in a place where resources are limited — and safety is a real concern?
www.youtube.com/watch?v=cDK7...
How do you build a community garden in a place where resources are limited — and safety is a real concern?
www.youtube.com/watch?v=cDK7...
📃 EFMC Literature Spotlight 📃
This edition’s contribution will focus on the recently published article “Novel Pyrazolo [1,5-a]−1,3,5-Triazine Derivatives as CDK7 Inhibitors: Synthesis and Biological Insights in Pancreatic Ductal Adenocarcinoma Models” by D. Carbone et al.
🔗 buff.ly/Glod3p1
This edition’s contribution will focus on the recently published article “Novel Pyrazolo [1,5-a]−1,3,5-Triazine Derivatives as CDK7 Inhibitors: Synthesis and Biological Insights in Pancreatic Ductal Adenocarcinoma Models” by D. Carbone et al.
🔗 buff.ly/Glod3p1
chemistry-europe.onlinelibrary.wiley.com
November 11, 2025 at 4:01 PM
📃 EFMC Literature Spotlight 📃
This edition’s contribution will focus on the recently published article “Novel Pyrazolo [1,5-a]−1,3,5-Triazine Derivatives as CDK7 Inhibitors: Synthesis and Biological Insights in Pancreatic Ductal Adenocarcinoma Models” by D. Carbone et al.
🔗 buff.ly/Glod3p1
This edition’s contribution will focus on the recently published article “Novel Pyrazolo [1,5-a]−1,3,5-Triazine Derivatives as CDK7 Inhibitors: Synthesis and Biological Insights in Pancreatic Ductal Adenocarcinoma Models” by D. Carbone et al.
🔗 buff.ly/Glod3p1
🔑 We also highlight how transcription-associated kinases (particularly CDK7, CDK9, CDK12 and CDK13), CTD phosphatases and innovative strategies such as targeted protein degradation are shaping the next generation of transcription-based therapies. 🛠️✨
July 7, 2026 at 8:18 AM
🔑 We also highlight how transcription-associated kinases (particularly CDK7, CDK9, CDK12 and CDK13), CTD phosphatases and innovative strategies such as targeted protein degradation are shaping the next generation of transcription-based therapies. 🛠️✨
Maybe CDK7 will be the next target. Looks promising in mice, human phase 1 ongoing, hopefully phase 2 coming soon to a research center near you (or not so near - we really need #Decentralized #ClinicalTrials) . #SABCS19 #oncoalert #bcsm
November 18, 2024 at 10:48 AM
Maybe CDK7 will be the next target. Looks promising in mice, human phase 1 ongoing, hopefully phase 2 coming soon to a research center near you (or not so near - we really need #Decentralized #ClinicalTrials) . #SABCS19 #oncoalert #bcsm
Objevili skrytou vazbu v regulaci RNA – zranitelné místo zpracování genetických informací ino.to/OuZ8eNj
Objevili skrytou vazbu v regulaci RNA – zranitelné místo zpracování genetických informací - Sciencemag.cz
Dříve se myslelo, že celý proces vystřižení nesmyslných částí RNA řídí pouze enzym CDK7. Tým z CEITE
ino.to
January 23, 2026 at 9:25 AM
Objevili skrytou vazbu v regulaci RNA – zranitelné místo zpracování genetických informací ino.to/OuZ8eNj
Combining CDK4/6 and CDK7 inhibitors enhances tumor control and boosts immune response in drug-resistant breast cancer models.
by Kim S, Son E (...) Yang HW et 2 al. in J Clin Invest #MedSky
👉 get more here
📖 read the article: https://www.jci.org/articles/view/188839
by Kim S, Son E (...) Yang HW et 2 al. in J Clin Invest #MedSky
👉 get more here
📖 read the article: https://www.jci.org/articles/view/188839
October 24, 2025 at 4:37 PM
Combining CDK4/6 and CDK7 inhibitors enhances tumor control and boosts immune response in drug-resistant breast cancer models.
by Kim S, Son E (...) Yang HW et 2 al. in J Clin Invest #MedSky
👉 get more here
📖 read the article: https://www.jci.org/articles/view/188839
by Kim S, Son E (...) Yang HW et 2 al. in J Clin Invest #MedSky
👉 get more here
📖 read the article: https://www.jci.org/articles/view/188839
Combining CDK4/6 and CDK7 inhibitors enhances tumor suppression and boosts anti-tumor immunity, offering hope for resistant breast cancers.
by Kim S, Son E (...) Yang HW et 2 al. in J Clin Invest #MedSky
👉 get more here
📖 read the article: https://www.jci.org/articles/view/188839
by Kim S, Son E (...) Yang HW et 2 al. in J Clin Invest #MedSky
👉 get more here
📖 read the article: https://www.jci.org/articles/view/188839
August 21, 2025 at 6:52 AM
Combining CDK4/6 and CDK7 inhibitors enhances tumor suppression and boosts anti-tumor immunity, offering hope for resistant breast cancers.
by Kim S, Son E (...) Yang HW et 2 al. in J Clin Invest #MedSky
👉 get more here
📖 read the article: https://www.jci.org/articles/view/188839
by Kim S, Son E (...) Yang HW et 2 al. in J Clin Invest #MedSky
👉 get more here
📖 read the article: https://www.jci.org/articles/view/188839